GT Biopharma Inc. (GTBP)
2.38
0.05 (2.15%)
At close: Apr 04, 2025, 1:19 PM
2.15% (1D)
| Bid | 2.25 |
| Market Cap | 6.04M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -6.94 |
| PE Ratio (ttm) | -0.34 |
| Forward PE | -0.19 |
| Analyst | Buy |
| Ask | 2.36 |
| Volume | 14,961 |
| Avg. Volume (20D) | 544,500 |
| Open | 2.20 |
| Previous Close | 2.33 |
| Day's Range | 2.20 - 2.38 |
| 52-Week Range | 1.72 - 10.66 |
| Beta | 1.31 |
About GTBP
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed ...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 27, 2018
Employees 1
Stock Exchange NASDAQ
Ticker Symbol GTBP
Website https://www.gtbiopharma.com
Analyst Forecast
According to 1 analyst ratings, the average rating for GTBP stock is "Buy." The 12-month stock price forecast is $11, which is an increase of 362.18% from the latest price.
Stock Forecasts1 month ago
+21.18%
GT Biopharma shares are trading higher after the c...
Unlock content with
Pro Subscription
3 months ago
+60.57%
GT Biopharma shares are trading higher. Roth MKM initiated coverage on the stock with a Buy rating and set its price target at $11.
